Kefauver Harris Amendments
Kefauver Harris Amendments - Related Videos
07:32
Monitoring Pedogenic Inorganic Carbon Accumulation Due to Weathering of Amended Silicate Minerals in Agricultural Soils.
0 Views •
Cited by 13 •
2021
The verification method described here is adaptable for monitoring pedogenic inorganic carbon sequestration in various agricultural soils amended with alkaline earth metal silicate-containing rocks, such as wollastonite, basalt, and olivine. This type of validation is essential for carbon credit programs, which can benefit farmers that sequester carbon in their fields.
10:07
Using Learning Outcome Measures to assess Doctoral Nursing Education
0 Views •
Cited by 2 •
2010
The structure and process for measuring student learning outcomes through customizable assessment rubrics is discussed and applied to a doctoral nursing education program.
09:29
Stereotactic Atlas-Guided Laser Capture Microdissection of Brain Regions Affected by Traumatic Injury
0 Views •
Cited by 3 •
2017
We describe the use of laser capture microdissection to obtain samples of distinct cell populations from different brain regions for gene and microRNA analysis. This technique allows the study of differential effects of traumatic brain injury in specific regions of the rat brain.
12:07
A Thin-skull Window Technique for Chronic Two-photon In vivo Imaging of Murine Microglia in Models of Neuroinflammation
0 Views •
Cited by 64 •
2010
We describe a method for repeatedly visualizing murine microglia and circulating monocytes in vivo over hours, days or weeks using transcranial two-photon microscopy. We demonstrate how to prepare a thinned-skull window that allows intermittent observation of quiescent microglia that can be activated by adjacent stereotactic injection of the HIV-1 regulatory protein Tat.
08:05
Testing Tactile Masking between the Forearms
0 Views •
Cited by 2 •
2016
Here we explore contralateral tactile masking between the forearms in which tactile detection thresholds are modulated by vibration applied to a remote site. The details of which remote sites have an effect can tell us about how the body is represented in the brain.
FAQs
The amendments require drug development to move beyond laboratory findings by demonstrating therapeutic benefit in controlled clinical studies. This creates an evidentiary connection between a medicine’s pharmacological effects and its performance in patients. The approach helps regulatory review consider whether observed benefits justify the medicine’s risks, rather than relying on laboratory results alone.
Safety and effectiveness answer different questions: safety concerns whether a medicine produces unacceptable harm, while effectiveness concerns whether it provides the intended therapeutic benefit. Requiring evidence for both prevents either consideration from standing alone. In pharmacology, this dual assessment supports a more complete evaluation of a drug’s acceptable risk and clinical value.
Informed consent protects people who participate in clinical trials by making consent a required part of the research framework. It complements the scientific requirements for controlled studies, ensuring that evidence used in regulatory decisions is generated alongside attention to participant protection. This links pharmacological investigation with ethical conduct during human research.
Controlled clinical studies provide evidence before marketing, but medicines also require attention to production quality and safety after wider use begins. Manufacturing requirements address the quality of the drug supplied, while adverse-event monitoring identifies safety information that may emerge later. Together, these measures extend oversight beyond the initial clinical evaluation.
Manufacturers must submit data from controlled clinical studies to the Food and Drug Administration as part of the regulatory process. These data support evaluation of safety and therapeutic effectiveness before marketing. The submission requirement makes clinical evidence a central basis for review and connects experimental pharmacology with decisions about whether a medicine can reach patients.
The framework links several stages of development: laboratory findings inform investigation, controlled clinical studies generate evidence in patients, and regulatory review assesses safety and effectiveness before marketing. Informed consent protects participants during trials, while manufacturing quality and postmarketing adverse-event monitoring continue oversight afterward. This sequence helps maintain continuity from early research through clinical use.
Postmarketing surveillance provides a continuing safety-monitoring function after a medicine enters broader clinical use. The amendments recognize that adverse-event information remains relevant beyond controlled trials, so monitoring does not end with marketing authorization. For pharmacology, this creates an ongoing connection between observed patient experience and the assessment of a medicine’s risks over time.